Preparation of pure human tumor necrosis factor and hybridomas producing monoclonal antibodies to human tumor necrosis factor

Patent 4870163 Issued on September 26, 1989. Estimated Expiration Date:

September 26, 2006. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.

Abstract Claims Description Full Text

Patent References

Anti-tumor agent from human serum and process
Patent #: 4309418
Issued on: 01/05/1982
Inventor: Green

Tumor localization and therapy with labeled antibodies to cell surface antigens
Patent #: 4444744
Issued on: 04/24/1984
Inventor: Goldenberg

Method for stabilizing a tumor necrosis factor and a stable aqueous solution or powder containing the same
Patent #: 4447355
Issued on: 05/08/1984
Inventor: Sakamoto , et al.

Process for producing target cell lysis factor and uses therewith
Patent #: 4495282
Issued on: 01/22/1985
Inventor: Ohnishi , et al.

Protein purification process and product
Patent #: 4503035
Issued on: 03/05/1985
Inventor: Pestka , et al.

Interferon epsilon
Patent #: 4614651
Issued on: 09/30/1986
Inventor: Jarvis, Jr. , et al.

Synergistic cytotoxic composition
Patent #: 4650674
Issued on: 03/17/1987
Inventor: Aggarwal , et al.

Human tumor necrosis factor
Patent #: 4677064
Issued on: 06/30/1987
Inventor: Mark , et al.

Highly purified human interleukin 2 and method Patent #: 4778879
Issued on: 10/18/1988
Inventor: Mertelsmann , et al.

Inventors

Application

No. 06/770808 filed on 08/29/1985

US Classes:

530/413, Immunological separation or affinity chromatography436/548, Monoclonal antibody530/351, Lymphokines, e.g., interferons, interlukins, etc.530/395, Glycoprotein, e.g., mucins proteoglycans, etc.530/415, Selective absorbtion, e.g., Ca phosphate sorbents, etc.530/829Blood

Examiners

Primary: Kepplinger, Esther M.
Assistant: Hoffer, Florina B.

Attorney, Agent or Firm

Sprung Horn Kramer & Woods

International Classes

C07K 16/18 (20060101)
C07K 14/435 (20060101)
C07K 14/525 (20060101)
C07K 16/24 (20060101)

Abstract

Human TNF(LuKII) having a specific activity of at least 1.5×105 units per milligram of total protein is produced by contacting a TNF-containing protein composition, which has been harvested from human cell lines of hematopoietic origin or recombinant origin, in separate adsorption stages with glass beads, lentil lectin bound to Sepharose, and procion red agarose, thereby selectively to adsorb TNF in each stage, while leaving some impurities unadsorbed, each contact stage being followed by contact of the adsorbent with an eluant thereby to obtain a solution of more highly purified TNF after each stage. The purified human TNF(LuKII) is used to produce monoclonal antibodies against TNF(LuKII) and such antibodies can be used to assay samples for the presence of TNF(LuKII).

Other References

Proc. Natl. Acad. Sci. USA, Williamson et al, vol. 80, pp. 5397-5401, 9/1983
Green et al, Proc. Nat. Acad. Sci. USA, vol. 73, 1976, pp. 381-385
Ruff et al, The Journal of Immunology, vol. 125, 1980, pp. 1671-1677
Mannel et al, Infection and Immunity, vol. 30, 1980, pp. 523-530
Chemical Abstracts, 105, 1986, 105:207220d, "An Enzyme-Linked Immunosorbent Assay for Recombinant Human Tumor Necrosis Factor Using Monoclonal Antibody", p. 451
J. of Biological Chemistry, vol. 260, Issue of 2/25/85, pp. 2345-2354, Aggarwal et al
Chemical Abstracts, vol. 105, No. 11, 9/15/86, p. 493, Abstract 95800j
Columbus, OH, US, B. Y. Rubin et al: "Human Tumor Recrosis Factor (LuKII): Recent Developments"
Chemical Abstracts, vol. 104, 1986, 86989e, "Monoclonal Antibody to Human Tumor Necrosis Factor", p. 534
Proc. Natl. Acad. Sci. USA, 82, pp. 6637-6641, 10/85, "Purification and Charac. of a Human Tumor Necrosis Factor from the LuKII Cell Line", Rubin et al
Aggarwal et al, "Human Lymphotoxin", The Journal of Biological Chemistry, vol. 259, Jan. 10, 1984, pp. 686-691
J. Cell Biology, 79, 67 (1978), to Green et al
Cancer Letters, 6, 235-240 (1979) to Green et al
Cancer Letters, 11, 345-350 (1981) to Green et al
Williams et al, J. Immunology, 130, 518-520 (1983)
AACR Abstracts, p. 211, No. 831 (1983) to Khan et al
E. A. Carswell et al, Proc. Natl. Acad. Sci. USA, 72, 3666-3670, (1975)
L. Helson, et al, Nature (London) 258, 731-732 (1975)
D. N. Mannel et al, Infect. Immun., 28, 204-211 (1980)
F. C. Kull and P. Cuatrecasas, J. Immunol., 126, 1279-1283 (1981)
K. Haranaka and N. Satomi, Jpn. J. Exp. Med., 51, 191-194 (1981)
N. Matthews and J. F. Watkins, Br. J. Cancer, 38, 302-309, 310-315 (1978)
J. M. Ostrove and G. E. Gifford, Proc. Soc. Exp. Biol. Med., 160, 354-358 (1979)
N. Matthews et al., Btr. J. Cancer, 42, 416-422 (1980)